After the close on Tuesday, GenMark (GNMK) preannounced above-consensus 1Q20 revenue given tailwinds from COVID-19 testing. The molecular diagnostics company is now expecting first quarter revenue of about $38.7 million, up about 80% year-over-year.It also raised its 2020 revenue guidance to $112- $122 million, up from the previously estimated $100- $110 million.“Our sample-to-answer test enables healthcare providers to determine if a patient has COVID-19 in under two hours and is a critical diagnostic solution for hospitals. I’m extremely proud of our team’s hard work throughout this crisis as we continue to work at maximum capacity to provide our ePlex SARS-CoV-2 …read more
Source:: Yahoo Finance
